How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

January 8, 2025

Long COVID Subsides in a Majority of Frontline Healthcare Workers

Image credit: RDNE, Pexels Undoubtedly, frontline healthcare workers (HCW) took on an enormous burden during

January 8, 2025 No Comments

Climate change linked with worse HIV prevention and care

New challenges in HIV prevention and care are emerging due to climate change, according to

January 8, 2025 No Comments

ACIP Expands Pneumococcal Vaccine Guidelines for Adults Aged 50 and Older

Serotypes included in pneumococcal vaccines currently recommended for adults — United States, 2024 Image credits: CDC

January 8, 2025 No Comments

Antimicrobial, Wound-Healing Agents Discovered Among Disparate Drug Classes

Image credit: Towfiqu Barbhuiya, Pexels Topical application of selective serotonergic reuptake inhibitors (SSRIs) and of

January 8, 2025 No Comments

LPOXY Therapeutics Acquires Assets to Advance C difficile Protection for Antibiotic Patients

Larry D Sutton, MD, PhD, CEO of LPOXY Therapeutics Image credits: LinkedIn LPOXY Therapeutics, Inc

January 8, 2025 No Comments

Early Release – Comparison of Contemporary and Historic Highly Pathogenic Avian Influenza A(H5N1) Virus Replication in Human Lung Organoids – Volume 31, Number 2—February 2025 – Emerging Infectious Diseases journal

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected

January 8, 2025 No Comments

Early Release – Ending Epidemics: A History of Escape from Contagion – Volume 31, Number 2—February 2025 – Emerging Infectious Diseases journal

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected

January 8, 2025 No Comments

Communicable disease threats report, 30 November

The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health

January 8, 2025 No Comments

Early Release – Diphtheria Toxin–Producing Corynebacterium ramonii in Inner-City Population, Vancouver, British Columbia, Canada, 2019–2023 – Volume 31, Number 2—February 2025 – Emerging Infectious Diseases journal

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected

January 8, 2025 No Comments

Communicable disease threats report, 7-13 December 2024, week 50

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7-13 December

January 8, 2025 No Comments

Long COVID Subsides in a Majority of Frontline Healthcare Workers

Climate change linked with worse HIV prevention and care

ACIP Expands Pneumococcal Vaccine Guidelines for Adults Aged 50 and Older

Antimicrobial, Wound-Healing Agents Discovered Among Disparate Drug Classes

LPOXY Therapeutics Acquires Assets to Advance C difficile Protection for Antibiotic Patients

Early Release – Comparison of Contemporary and Historic Highly Pathogenic Avian Influenza A(H5N1) Virus Replication in Human Lung Organoids – Volume 31, Number 2—February 2025 – Emerging Infectious Diseases journal

Early Release – Ending Epidemics: A History of Escape from Contagion – Volume 31, Number 2—February 2025 – Emerging Infectious Diseases journal

Communicable disease threats report, 30 November

Early Release – Diphtheria Toxin–Producing Corynebacterium ramonii in Inner-City Population, Vancouver, British Columbia, Canada, 2019–2023 – Volume 31, Number 2—February 2025 – Emerging Infectious Diseases journal

Communicable disease threats report, 7-13 December 2024, week 50

Schedule an Appointment

Quick Links

Patient Forms

Contact Us